Ray Therapeutics Announces Promotion of Jenny Holt to Chief Development Officer

Ray Therapeutics Announces Promotion of Jenny Holt to Chief Development Officer

Ray Therapeutics Announces Promotion of Jenny Holt to Chief Development Officer

SAN FRANCISCO–(BUSINESS WIRE)–Ray Therapeutics, a leading optogenetics medicines company, today announced the promotion of Jenny Holt to Chief Development Officer.

“Since joining the Company in 2022 as Senior Vice President, Program Portfolio Management, Jenny has demonstrated exceptional leadership and has played a critical role in the growth and accomplishments of Ray Therapeutics,” said Paul Bresge, Chief Executive Officer. “She has played an integral part in advancing our programs and I am pleased to announce her well-deserved promotion to Chief Development Officer. I look forward to continuing to work with her alongside the rest of Ray’s executive leadership team as we advance our first candidate for degenerative retinal diseases into the clinic.”

“I joined Ray Therapeutics because of the team’s commitment to driving a novel class of optogenetics-based therapies into the clinic for patients with huge unmet medical need,” said Holt. “I am honored to continue contributing to the company’s mission to develop treatments for patients with retinal blindness.”

Jenny Holt is an experienced biotech and pharmaceutical executive with more than 25 years of experience primarily in gene therapies, ophthalmology, and oncolytic viral research. Prior to joining Ray Therapeutics, Jenny was previously at 4D Molecular Therapeutics, a leading AAV-based gene therapy company, where she managed five gene therapy products from discovery to early-stage clinical development. She also was a co-founder at Ignite Immunotherapy which was acquired by Pfizer in 2019. She started her career in scientist positions at UCSF Gladstone Institutes, Onyx Pharmaceuticals, and Novartis Institute of Biomedical Research. She is a graduate of UC Santa Barbara.

About Ray Therapeutics

Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company is developing its lead candidate RTx-015 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical need. Our mission is to use optogenetics to restore vision, independent of genetic mutation for patients with inherited retinal diseases. Ray Therapeutics is based in San Francisco, CA. For additional information, visit www.raytherapeutics.com.



Kimberly Ha

KKH Advisors